Jan Delaval please

Access DB# 59923

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabiha Qazi Examiner #: 74141 Date: 2/5/02
Art Unit: 1616 Phone Number 30 5-3910 Serial Number: 09/899,702 & 09/779,331
Mail Box and Bldg/Room Location: 3807 2D19, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Estrogenic Compds as Antiangiogenic agents
Inventors (please provide full names): D'Amato et al.

Earliest Priority Filing Date: 7/5/01

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Pl. note 09/899,702 Contains NO Rh_1 + Rh_2 substituents

Elected species

09/899,702
compd of claim

09/779,331
compd of claim

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

DENIED (STIC) FEB - 8 01

Please see attached sheets

thank you

****

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4498
Searcher Location:
Date Searcher Picked Up: 2/19/02
Date Completed: 2/19/02
Searcher Prep & Review Time:
Clerical Prep Time: 25
Online Time: 75

Type of Search

NA Sequence (#)
AA Sequence (#)
Structure (#) ✓
Bibliographic
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable

STN
Dialog
Questel/Orbit
Dr.Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

PTO-1590 (8-01)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:28:37 ON 19 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   18 FEB 2002  HIGHEST RN 393508-26-4
DICTIONARY FILE UPDATES:  18 FEB 2002  HIGHEST RN 393508-26-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

The P indicator for Preparations was not generated for all of the
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between
12/27/01 and 1/23/02.  Use of the P indicator in online and SDI searches
during this period, either directly appended to a CAS Registry Number
or by qualifying an L-number with /P, may have yielded incomplete results.
As of 1/23/02, the situation has been resolved.  Also, note that searches
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files
incorporating CAS Registry Numbers with the P indicator between 12/27/01
and 1/23/02, are encouraged to re-run these strategies.  Contact the
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,
worldwide, or send an e-mail to help@cas.org for further assistance or to
receive a credit for any duplicate searches.

=> d sta que l29
L13          32 SEA FILE=REGISTRY ABB=ON  PLU=ON  (1035-77-4/BI OR 117048-59-6/
                BI OR 1236-72-2/BI OR 15833-07-5/BI OR 16205-32-6/BI OR
                165619-07-8/BI OR 165619-10-3/BI OR 165619-11-4/BI OR 165619-22
                -7/BI OR 165619-23-8/BI OR 192062-02-5/BI OR 192062-12-7/BI OR
                192062-13-8/BI OR 192062-14-9/BI OR 192062-15-0/BI OR 192062-20
                -7/BI OR 22415-44-7/BI OR 26788-23-8/BI OR 26890-04-0/BI OR
                302799-37-7/BI OR 362-07-2/BI OR 362-08-3/BI OR 383414-35-5/BI
                OR 50-27-1/BI OR 50-28-2/BI OR 518-28-5/BI OR 53-16-7/BI OR
                56-53-1/BI OR 57-63-6/BI OR 5976-67-0/BI OR 64-86-8/BI OR
                95041-90-0/BI)
L14          27 SEA FILE=REGISTRY ABB=ON  PLU=ON  L13 AND C5-C6-C6-C6/ES
L16             STR
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov



CH2—OH
@22 23

NH—Ak
@24 25



Ak—Cy—G4
@65 64 63

Cy—G4
@62 61

O—G5—G4
@66 67 68

N~N~N
@30 31 32

C≡C—G3
@33 34 35

Ak—Cy
@36 @37

C=C—G3
@38 39 40

Ak—C=C
@41 42 43

Cy—C=C
@44 45 46

Ak—Cy—C=C
@50 47 48 49

C≡C
@51 52

O—G3
@53 54

Ak—G4
@55 56

VAR G1=H/X/CN/AK/OH/22/NH2/24/26
VAR G2=30/CN/33/38/41/44/50/51/53/55/62/65/66
VAR G3=AK/CY/36
VAR G4=OH/NH2/X/58
VAR G5=AK/CY/36-66 37-68
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 1
CONNECT IS M1 RC AT 7
CONNECT IS M1 RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L18 394 SEA FILE=REGISTRY CSS FUL L16
L19 STR



























VAR G1=C/18/20/23/26
VAR G2=C/31/34/36/39/45/47/49/52
VAR G3=AK/CY/43
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 2
CONNECT IS M1 RC AT 3
CONNECT IS M1 RC AT 4
CONNECT IS M1 RC AT 14
CONNECT IS M1 RC AT 15
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE
L21 152 SEA FILE=REGISTRY SUB=L18 CSS FUL L19
L22 STR





VAR G1=C/25/19/22/27/33/37/39/42/46
VAR G2=AK/CY/31
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 1
CONNECT IS M1 RC AT 2
CONNECT IS M1 RC AT 3
CONNECT IS M1 RC AT 4
CONNECT IS M1 RC AT 7
CONNECT IS M1 RC AT 14
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 46

STEREO ATTRIBUTES: NONE
L24 88 SEA FILE=REGISTRY SUB=L21 CSS FUL L22
L25 13 SEA FILE=REGISTRY ABB=ON PLU=ON L14 AND L24
L27 75 SEA FILE=REGISTRY ABB=ON PLU=ON L24 NOT L25
L28 68 SEA FILE=REGISTRY ABB=ON PLU=ON L27 NOT (IDS/CI OR (D OR T)/ELS OR 11C# OR 13C# OR 14C#)
L29 81 SEA FILE=REGISTRY ABB=ON PLU=ON (L25 OR L28)

=> d his

(FILE 'HOME' ENTERED AT 14:20:04 ON 19 FEB 2002)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:20:15 ON 19 FEB 2002
E DAMATO/AU
E D AMATO/AU
L1 65 S E74,E77,E84,E86,E87
E AMATO/AU
L2 2 S E36
L3 28 S E133,E135,E140,E141
E VARMA R/AU
L4 124 S E3,E10,E11,E12
L5 133 S E45-E47
E HAUGWITZ R/AU
L6 147 S E3-E11
E CUSHMAN M/AU

```
L7          201 S E3-E6,E8,E9,E10
L8          685 S L1-L7
L9           14 S L8 AND ?ESTROGEN?
L10          42 S L8 AND ?ANGIO?
L11           4 S L9 AND L10
L12           1 S L11 AND ESTROGEN?/TI
                SEL RN

    FILE 'REGISTRY' ENTERED AT 14:24:13 ON 19 FEB 2002
L13          32 S E1-E32
L14          27 S L13 AND C5-C6-C6-C6/ES
L15           1 S L14 AND C21H28O2
                E C21H28O2/MF
L16             STR
L17           9 S L16 CSS SAM
L18         394 S L16 CSS FUL
                SAV L18 QAZ899/A
L19             STR
L20           5 S L19 CSS SAM SUB=L18
L21         152 S L19 CSS FUL SUB=L18
                SAV L21 QAZ899A/A
L22             STR
L23           4 S L22 CSS SAM SUB=L21
L24          88 S L22 CSS FUL SUB=L21
                SAV L24 QAZ899B/A
L25          13 S L14 AND L24
L26          14 S L14 NOT L25
L27          75 S L24 NOT L25
L28          68 S L27 NOT (IDS/CI OR (D OR T)/ELS OR 11C# OR 13C# OR 14C#)
L29          81 S L25,L28
L30          80 S L29 NOT L15
                SAV L30 QAZ899C/A

    FILE 'HCAOLD' ENTERED AT 15:15:35 ON 19 FEB 2002
L31           0 S L15
L32          72 S L30

    FILE 'HCAPLUS' ENTERED AT 15:15:58 ON 19 FEB 2002
L33           2 S L15
L34           2 S L8 AND L33
L35         489 S L30
                E ANGIOGENESIS/CT
                E E3+ALL
L36        5343 S E5+NT
                E E10+ALL
L37        1959 S E4+NT
L38       73654 S E3+NT
                E E3+ALL
L39       77026 S E4
L40      165292 S E501+NT
L41          13 S L35 AND L36
L42          83 S L35 AND L37-L41
L43          38 S L35 AND ANGIOGENES?
L44           3 S L35 AND ANTIANGIOGENES?
L45          15 S L35 AND ANTIANGIO?
L46          39 S L41,L43-L45
L47          33 S L42 AND L46
L48          49 S L35 AND P/DT
L49         358 S L35 AND ?ESTROGEN?
L50          67 S L49 AND L41-L48
L51          19 S L50 AND L46
L52          30 S L35 AND ANGIO?/CW
L53          29 S L52 AND L41-L48,L50,L51
L54          30 S L34,L53
L55          30 S L54 AND L33-L54
L56           2 S L55 AND L34
```

Species

Species

```
L57          28 S L55 NOT L56
L58          81 S L41-L48,L50-L55 NOT L57
L59          64 S L30 (L) THU/RL
L60          36 S L59 AND L58
L61          16 S L60 AND (1 OR 63)/SC
L62          13 S L60 AND (1 OR 63)/SX
L63          24 S L61,L62
L64          24 S L59 AND ?ANGIO?
L65          24 S L64 AND L33-L63
L66          23 S L65 NOT 27/SC
L67          24 S L33,L34,L66 AND L33-L66
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 15:28:10 ON 19 FEB 2002
L68          17 S E1-E17
L69          16 S L68 NOT L15

     FILE 'REGISTRY' ENTERED AT 15:28:37 ON 19 FEB 2002

=> d ide can l15

L15  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   165619-11-4  REGISTRY
CN   Estra-1,3,5(10)-triene-3,17-diol, 2-(1E)-1-propenyl-, (17.beta.)- (9CI)
     (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Estra-1,3,5(10)-triene-3,17-diol, 2-(1-propenyl)-, [2(E),17.beta.]-
OTHER NAMES:
CN   NSC 667047
FS   STEREOSEARCH
MF   C21 H28 O2
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.
```

← hit compounds for L67, 1-24

Species




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               2 REFERENCES IN FILE CA (1967 TO DATE)
               2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  136:64669

REFERENCE   2:  123:112496


=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:28:54 ON 19 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 18 Feb 2002 VOL 136 ISS 8
FILE LAST UPDATED: 17 Feb 2002 (20020217/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l70 bib abs hitrn tot

L70 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS
AN 2002:11127 HCAPLUS
DN 136:64669
TI **Estrogenic** compounds as **antiangiogenic** agents
IN **D'Amato, Robert J.; Varma, Ravi K.; Haugwitz, Rudiger G.; Cushman, Mark**
PA USA
SO U.S. Pat. Appl. Publ., 14 pp., Cont. of U.S. Ser. No. 154,322, abandoned.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002294	A1	20020103	US 2001-899702	20010705
PRAI US 1997-59916	P	19970924		
US 1998-154322	B1	19980916		

OS MARPAT 136:64669
GI



I



II

AB 2-Methoxyestradiol derivs., such as I [R1, R3 = H, Cl, Br, I, F, CN, alkyl, OH, CH2OH, NH2, alkylamino; R2 = N3, CN, C.tplbond.CR, C=CHR, RCH=CH2, C.tplbond.CH, OR, R-R1, OR-R1 (R = alkyl, R1 = OH, NH2, Cl, Br, I, F, CF3); Z = CH, COH, CR2-OH (R2 = alkyl, aralkyl); Z' = CH2, CO, CH(OH); C=NOH, C=NOR5, CHC.tplbond.N, CHNR5R5 (R5 = H, alkyl, aralkyl)], were used for treating mammalian disease characterized by undesirable **angiogenesis**. Thus, 2-methoxyestradiol (II) showed inhibition of tubulin polymn. (IC50 = 3.6.+-.0.4 .mu.M), inhibition of colchicine binding to tubulin (1.9.+-.0.2 .mu.M) and antitumor activity against breast, CNS, melanoma, ovarian tumor cell assay in vitro.

IT **362-07-2**, NSC 659853 **362-08-3**, 2-Methoxyestrone
22415-44-7 165619-07-8, NSC 671043 **165619-11-4**
, NSC 667047 **192062-02-5**, NSC 682429 **192062-12-7**, NSC
679431 **192062-13-8**, NSC 681684 **192062-14-9**, NSC 680185
192062-15-0, NSC 681683 **192062-20-7**, NSC 683125
302799-37-7, NSC 683688 **383414-35-5**, NSC 678473
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**estrogenic** compds. as **antiangiogenic** agents)

L70 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS
AN 1995:592276 HCAPLUS
DN 123:112496
TI Synthesis, Antitubulin and Antimitotic Activity, and Cytotoxicity of Analogs of 2-Methoxyestradiol, an Endogenous Mammalian Metabolite of Estradiol That Inhibits Tubulin Polymerization by Binding to the Colchicine Binding Site
AU **Cushman, Mark**; He, Hu-Ming; Katzenellenbogen, John A.; Lin, Chii M.; Hamel, Ernest
CS Department of Medicinal Chemistry, Purdue University, West Lafayette, IN, 47907, USA
SO J. Med. Chem. (1995), 38(12), 2041-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB In order to define the structural parameters assocd. with the antitubulin activity and cytotoxicity of 2-methoxyestradiol, a mammalian metabolite of estradiol, an array of analogs was synthesized and evaluated. The potencies of the new congeners as inhibitors of tubulin polymn. and colchicine binding were detd. using tubulin purified from bovine brain, and the cytotoxicities of the new compds. were studied in a variety of cancer cell cultures. Maximum antitubulin activity was obsd. in estradiols having unbranched chain substituents at the 2-position with three non-hydrogen atoms. 2-Ethoxyestradiol and 2-((E)-1-propenyl)estradiol were substantially more potent than 2-methoxyestradiol itself. The tubulin polymn. inhibitors in this series displayed significantly higher cytotoxicities in the MDA-MB-435 breast cancer cell line than in the other cell lines studied. The potencies of the analogs as cytotoxic and antimitotic agents in cancer cell cultures correlated with their potencies as inhibitors of tubulin polymn., supporting the hypothesis that inhibition of tubulin polymn. is the mechanism of the cytotoxic action of 2-methoxyestradiol and its congeners. Several of the more potent analogs were tested in an **estrogen** receptor binding assay, and their affinities relative to estradiol were found to be very low.
IT **165619-11-4P 165619-12-5P 165619-13-6P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of methoxyestradiol)
IT **362-07-2P 165619-07-8P 165619-08-9P**
165619-09-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of methoxyestradiol)

=> d l71 bib abs hitrn tot

L71 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:798040 HCAPLUS
DN 135:339222
TI Inhibition of abnormal cell proliferation with camptothecin or a derivative, analog, metabolite, or prodrug thereof, and combinations

including camptothecin
IN Rubinfeld, Joseph
PA Supergen, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001080843	A2	20011101	WO 2001-US12848	20010419

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-553710 A1 20000420
AB A method for treating diseases assocd. with abnormal cell proliferation comprises delivering to a patient in need of treatment a compd. selected from 20(S)-comptothecin, an analog of 20(S)-comptothecin, a deriv. of 20(S)-camptothecin, a prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amt. of one or more agents selected form the group consisting of alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-**angiogenesis** agent and biol. agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases assocd. with abnormal **angiogenesis** .
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

L71 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:769051 HCAPLUS
DN 136:112738
TI 2-Methoxyestradiol: A novel endogenous chemotherapeutic and anti-**angiogenic** agent
AU Pribluda, Victor S.; LaVallee, Theresa M.; Green, Shawn J.
CS EntreMed, Rockville, MD, USA
SO New Angiotherapy (2002), 387-407. Editor(s): Fan, Tai-Ping D.; Kohn, Elise C. Publisher: Humana Press Inc., Totowa, N. J.
CODEN: 69BYCE
DT Conference; General Review
LA English
AB A review which discusses the properties of 2-methoxyestradiol, which is a part of a new generation of anti-cancer agents. The 2-methoxyestradiol is now recognized as a potent endogenous antimitogen and has the ability to selectively inhibit the growth of rapidly proliferating endothelial cells. Its candidacy as a viable antimitotic drug is supported by exptl. evidence showing that 2-methoxyestradiol is orally-active, and at therapeutic doses shows minimal, if any, toxicity.
IT **362-07-2**, 2-Methoxyestradiol
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methoxyestradiol as chemotherapeutic and anti-**angiogenic** agent)
RE.CNT 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:746919 HCAPLUS
DN 136:31843
TI **Angiogenetic** and anti-**angiogenetic** effects of estradiol and its metabolites
AU Mueck, A. O.; Seeger, H.; Lippert, C.; Wallwiener, D.
CS Section of Endocrinology and Menopause, University Hospital, Tuebingen, 72076, Germany
SO Journal of Clinical and Basic Cardiology (2001), 4(2), 153-155
CODEN: JCBCFT; ISSN: 1561-2775
PB Krause & Pachernegg GmbH
DT Journal
LA English
AB Atherosclerotic plaques in later stages exhibit marked presence of new micro vessels. Thus **angiogenesis** may be important for the development of atherosclerotic plaques and long-term anti-**angiogenetic** therapy may present an effective new anti-atherosclerotic approach. 2-Methoxyestradiol, an endogenous estradiol metabolite, has already been shown to be an effective anti-**angiogenetic** substance. In the present study 14 endogenous estradiol metabolites were tested on their **angiogenetic** and anti-**angiogenetic** properties and compared to the effect of their parent substance, 17.beta.-estradiol. Endothelial cells from human umbilical veins were used for the expts. 17.beta.-Estradiol showed a biphasic reaction on the proliferation of vascular endothelial cells. At low concn. it stimulated and at high concns. it inhibited cell growth. The same pattern was obsd. for the hydroxylated A-ring metabolites. Methylation of these metabolites, however, completely abrogated the anti-proliferative effect at high concns., except for the metabolite 2-hydroxyestradiol. For the D-ring metabolites no marked changes were obsd. These results indicate that in addn. to 2-methoxyestradiol other endogenous estradiol metabolites are potent anti-**angiogenetic** substances at high dosages. Since some of these metabolites are almost devoid of any **estrogenic** property, they may be useful for long-term anti-**angiogenetic** therapy in both men and women. This should be of interest to clin. pharmacol. research since it points to potential new aspects in the treatment of cardiovascular diseases.
IT **362-07-2**, 2-Methoxyestradiol **362-08-3**, 2-Methoxyestrone
RL: PAC (Pharmacological activity); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**angiogenesis** and anti-**angiogenesis** effects of estradiol and metabolites)
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:360984 HCAPLUS
DN 135:56155
TI Oestradiol metabolites: Effects on airway remodelling
AU Stewart, A. G.; Vlahos, R.; Fernandes, D. J.; Hughes, R. A.
CS Department of Pharmacology, University of Melbourne, Australia
SO Prog. Respir. Res. (2001), 31(New Drugs for Asthma, Allergy and COPD), 102-105
CODEN: PRRRAE; ISSN: 1422-2140
PB S. Karger AG
DT Journal; General Review
LA English
AB A review with 25 refs. Airway wall remodelling is a significant contributor to the airway hyperresponsiveness in asthma and hence to asthma symptoms. Existing anti-asthma agents (glucocorticoids) appear to have insufficient efficacy in the regulation of smooth muscle proliferation and other aspects of airway wall remodelling in severe asthma. Thus, agents that regulate airway wall remodelling will add significantly to the choice of preventative therapies available for more severe asthma. The anti-**angiogenic**, anti-proliferative estradiol metabolite, 2-methoxyestradiol, is a candidate prophylactic

anti-asthma agent that may more specifically target the airway wall remodelling process.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(estradiol metabolites effects on airway remodelling in relation to asthma)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:310080 HCAPLUS
DN 135:116756
TI The **antiangiogenic** property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
AU Sweeney, Christopher J.; Miller, Kathy D.; Sissons, Sean E.; Nozaki, Shinichi; Heilman, Douglas K.; Shen, Jianzhao; Sledge, George W., Jr.
CS Department of Medicine, Indiana University, Indianapolis, IN, 46202, USA
SO Cancer Res. (2001), 61(8), 3369-3372
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examd. the **antiangiogenic** activity of docetaxel. Docetaxel inhibited endothelial cell proliferation and tubule formation in vitro in a dose-dependent fashion. Docetaxel treatment also inhibited **angiogenesis** in an in vivo Matrigel plug assay. The endothelial stimulating factors, vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor are able to protect endothelial cells from the **antiangiogenic** properties of docetaxel. This protective effect can be overcome by a recombinant humanized monoclonal antibody directed against VEGF in both in vitro and in vivo models. Similarly, combination of docetaxel with the **antiangiogenic** agent 2-methoxyestradiol also overcomes the protective effect of VEGF in both in vitro and in vivo models. These data suggest that microenvironmental factors (e.g., local release of VEGF and basic fibroblast growth factor) could play a role in decreasing the **antiangiogenic** effects of docetaxel, whereas agents such as 2-methoxyestradiol and recombinant humanized monoclonal antibody directed against VEGF may reverse this protective effect.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**antiangiogenic** property of docetaxel is synergistic with a humanized MAb against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:43056 HCAPLUS
DN 135:71332
TI 2-Methoxyestradiol: an endogenous **antiangiogenic** and antiproliferative drug candidate
AU Pribluda, Victor S.; Gubish, Edward R., Jr.; LaVallee, Theresa M.; Treston, Anthony; Swartz, Glenn M.; Green, Shawn J.
CS EntreMed Inc., Rockville, MD, USA
SO Cancer Metastasis Rev. (2000), 19(1/2), 173-179
CODEN: CMRED4; ISSN: 0167-7659
PB Kluwer Academic Publishers
DT Journal; General Review
LA English

AB A review, with 43 refs. 2-Methoxyestradiol (2ME2), once considered an inactive end-metabolite of estradiol, has recently emerged as a very promising agent for cancer treatment. It is orally active in a wide range of tumor models, and inhibits tumor growth at doses showing no clin. signs of toxicity. 2ME2 targets both the tumor cell and endothelial cell compartments by inducing apoptosis in rapidly proliferating cells and inhibiting blood vessel formation at several stages in the **angiogenic** cascade. Moreover, the ability of 2ME2 to inhibit metastatic spread in several models adds to its therapeutic value for cancer treatment at various stages of the disease. Though the mechanism of action is still undefined, several potential mol. targets and pathways of activation have been suggested.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methoxyestradiol as endogenous **antiangiogenic** and antiproliferative drug candidate)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:595071 HCAPLUS
DN 133:305736
TI 2-Methoxyestradiol blocks **estrogen**-induced rat pituitary tumor growth and tumor **angiogenesis**: possible role of vascular endothelial growth factor
AU Banerjee, Sushanta K.; Zoubine, Mikhail N.; Sarkar, Dipak K.; Weston, Allan P.; Shah, Jamshed H.; Campbell, Donald R.
CS Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA
SO Anticancer Res. (2000), 20(4), 2641-2645
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
AB Natural and synthetic **estrogens** have been assocd. with several types of human and animal cancers including prolactin-secreting pituitary tumors in Fischer 344 rats. These prolactin-secreting tumors are highly **angiogenic** and their growth is **angiogenic** dependent. In the present study we have utilized this model to evaluate the effect of 2-methoxyestradiol (2-ME), an endogenous **estrogen** metabolite that is a potent inhibitor of endothelial cell proliferation in vitro, on **estrogen**-induced pituitary tumor growth and **angiogenesis**. Adult female rats were implanted (s.c.) with a silastic capsule contg. estradiol-17.beta. (E2). After seven days of const. E2 exposure animals were injected (s.c.) daily with 25 mg/kg of 2-ME and killed either three or 8 days later. Changes in pituitary wt. and proliferating cell nuclear antigen (PCNA) labeling index indicated growth while degree of **angiogenesis** was detd. immunohistochem. using factor VIII related antigen. The results indicate that 2-ME inhibited **estrogen**-induced lactotroph growth by 32% and tumor **angiogenesis** by 89%. Furthermore, vascular endothelial growth factor (VEGF) expression, evaluated by immunohistochem. anal., was down-regulated concomitant with tumor **angiogenic** suppression. These studies suggest that 2-ME may have therapeutic potential for hormone-induced cancer and that its **angiostatic** activity may be modulated through down-regulation of VEGF expression.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methoxyestradiol blocks **estrogen**-induced rat pituitary tumor growth and tumor **angiogenesis** and VEGF role therein)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:592560 HCAPLUS
DN 133:198575
TI Compositions and methods for use in targeting vascular destruction
IN Pero, Ronald W.; Sherris, David
PA Oxigene, Inc., USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000048606	A1	20000824	WO 2000-US3996	20000216
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1152764	A1	20011114	EP 2000-914606	20000216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1999-120478 P 19990218
WO 2000-US3996 W 20000216
OS MARPAT 133:198575
AB Treatment of warm-blooded animals having a tumor or non-malignant hypervascularization, by administering a sufficient amt. of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(prodrugs for use in targeting vascular destruction)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:261865 HCAPLUS
DN 133:14181
TI Enhancement of radiation effects in vitro by the **estrogen** metabolite 2-methoxyestradiol
AU Amorino, George P.; Freeman, Michael L.; Choy, Hak
CS Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
SO Radiat. Res. (2000), 153(4), 384-391
CODEN: RAREAE; ISSN: 0033-7587
PB Radiation Research Society
DT Journal
LA English
AB 2-Methoxyestradiol (2-ME) is an endogenous estradiol metabolite that disrupts microtubule function, suppresses murine tumors, and inhibits **angiogenesis**. Since some microtubule inhibitors have been shown to alter radiosensitivity, we have evaluated 2-ME as a radiation enhancer in vitro. H460 human lung cancer cells were plated, treated with 2-ME for 24 h, and irradiated; then colony-forming ability was assessed. The radiation dose enhancement ratios (DERs) using this protocol were 1.3, 1.8 and 2.1 for 1, 1.5 and 2 .mu.M 2-ME, resp. Using a single-cell plating protocol, the resp. DERs were 1.2, 1.5 and 1.8. The parent compd. of 2-ME, .beta.-estradiol, did not enhance radiation effects at equally

cytotoxic doses. Isobologram anal. showed that 1 .mu.M 2-ME was additive with radiation, but that 1.5 and 2 .mu.M were synergistic. Cell cycle anal. showed a dose-dependent increase in the percentage of cells in the radiosensitive G2/M phase after a 24-h treatment with 2-ME; a threefold increase in the percentage of cells in G2/M phase was obsd. using 2 .mu.M 2-ME. Treatment with 2 .mu.M 2-ME almost completely inhibited repair of sublethal damage (SLD) as shown using split-dose recovery. Radiosensitive, repair-deficient murine SCID (severe combined immunodeficient) cells did not show enhancement of radiation effects with 2 .mu.M 2-ME, but enhancement was obsd. in the wild-type parental cells (CB-17). SCID cells complemented with human DNA-dependent protein kinase restored radioenhancement by 2-ME. In addn., MCF-7 breast cancer cells were also radiosensitized by 2 .mu.M 2-ME (DER = 2.1). These data suggest that 2-ME is a potential radiation sensitizer, in addn. to its previously reported antitumor and **antiangiogenic** properties. We have verified the **antiangiogenic** activity of 2-ME in vitro using human endothelial cells. Based on these results, we hypothesize that the mechanism of radiation enhancement may involve redistribution of cells into G2/M phase by 2-ME, and that the resulting population of cells is repair-deficient and thus radiosensitive.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**estrogen** metabolite 2-methoxyestradiol enhancement of radiation effects)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:227537 HCAPLUS
DN 132:262172
TI Use of **neoangiogenesis** markers for diagnosis and treatment of tumors
IN Krause, Werner; Muschick, Peter
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT **Patent**
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000018439	A2	20000406	WO 1999-EP7198	19990929
WO 2000018439	A3	20000914		

W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

DE 19845798	A1	20000413	DE 1998-19845798	19980929
PRAI DE 1998-19845798	A	19980929		

AB **Neoangiogenesis** markers (i.e. antibodies or receptors for e.g. vascular endothelial growth factor, placenta growth factor, acidic or basic FGF, transforming growth factor .alpha. or .beta., hepatocyte growth factor, insulin-like growth factor I, glycoprotein B61, protein LERK-1, flk-1 receptor, etc.) or partial sequences thereof and **antiangiogenic** compds. and factors such as paclitaxel, endostatin, fibronectin peptide, and fumagillin are conjugated with active agents such as chemotherapeutic agents, radiosensitizers, photosensitizers, antibodies, oligonucleotides, radioactive metal complexes, etc., which may be bound to carriers, for treatment of tumors. Likewise, **neoangiogenesis** markers may be conjugated to diagnostic agents such as MRI, radiog., ultrasound, or near-IR contrast agents for tumor diagnosis. Thus, N',N',N''',N'''-tetrakis(tert-butoxycarboxymethyl)-N''-

(hydroxycarboxymethyl)diethylenetriamine was converted to its N-hydroxysuccinimide ester, coupled to a Thy-1 antibody, complexed with 186Re, and injected i.v. into rabbits for detection of implanted VX2 tumors by scintigraphy with a gamma camera.

IT **362-07-2**
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(**angiogenesis** marker; use of **neoangiogenesis** markers for diagnosis and treatment of tumors)

L71 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:144722 HCAPLUS
DN 132:185454
TI Use of anti-**angiogenic** agents for inhibiting vessel wall injury
IN Brown, Charles L., III; Gorlin, Steve
PA Global Vascular Concepts, Inc., USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000010552	A2	20000302	WO 1999-US19218	19990824
WO 2000010552	A3	20001123		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9956871	A1	20000314	AU 1999-56871	19990824
PRAI US 1998-97579	P	19980824		
WO 1999-US19218	W	19990824		

AB Use of anti-**angiogenic** agents to inhibit an undesirable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-**angiogenic** agents into the endothelial tissues of blood vessels of the living body.

IT **362-07-2**, 2-Methoxyestradiol
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(anti-**angiogenic** agents for inhibiting vessel wall injury)

L71 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:736476 HCAPLUS
DN 131:346535
TI Use of neomycin for treating **angiogenesis**-related diseases
IN Hu, Guo-Fu; Vallee, Bert L.
PA The Endowment for Research In Human Biology, Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9958126	A1	19991118	WO 1999-US10269	19990511

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9939804 A1 19991129 AU 1999-39804 19990511
EP 1083896 A1 20010321 EP 1999-922915 19990511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
PRAI US 1998-84921 P 19980511
WO 1999-US10269 W 19990511

AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat **angiogenesis**-related diseases, which are characterized by excessive, undesired or inappropriate **angiogenesis** or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-**angiogenic** agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-**angiogenic** activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited **angiogenin** -induced **angiogenesis** in the chorioallantoic membrane (CAM) assay. Neomycin inhibits **angiogenin**-induced **angiogenesis** mainly through inhibition of nuclear translocation of **angiogenin**.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(neomycin, its analogs and other agents for treatment of **angiogenesis**-related diseases)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:672339 HCAPLUS
DN 132:520
TI **Angiostatic** activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization
AU McNatt, Loretta G.; Weimer, Lori; Yanni, John; Clark, Abbot F.
CS Alcon Laboratories, Inc., Fort Worth, TX, USA
SO J. Ocul. Pharmacol. Ther. (1999), 15(5), 413-423
CODEN: JOPTFU; ISSN: 1080-7683
PB Mary Ann Liebert, Inc.
DT Journal
LA English

AB Ocular neovascular diseases represent a major cause of blindness in the world. **Angiostatic** steroids are a unique class of compds. which inhibit the formation of new blood vessels in various models, including ocular models of **angiogenesis**. In search of potent new anti-**angiogenic** agents for the treatment of ocular neovascular disease, a large group of steroids were evaluated for **angiostatic** activity in the chick embryo CAM model. **Angiostatic** activity was found among all steroid classes included in the study. There was a good correlation between the **angiostatic** efficacies of 15 diverse steroids tested in the chick CAM and in the rabbit LPS-induced corneal pocket models of neovascularization ($r=0.76$, $p=0.01$). These studies show that potent **angiostatic** steroids inhibit neovascularization in two different animal models, suggesting a common mechanism of action. Glucocorticoid therapy is sometimes assocd. with ocular side effects. Two of the most potent **angiostatic** steroids, AL-3789 and AL-4940, were evaluated for glucocorticoid-mediated anti-inflammatory activity in the in vitro U937 cell model of LPS-induced IL-1 induction and found to be devoid of glucocorticoid activity.

Angiostatic steroids which lack glucocorticoid activity should be attractive drug candidates for treating ocular neovascular disease.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**angiostatic** activity of steroids in chick embryo CAM and rabbit cornea models of neovascularization)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:48631 HCAPLUS
DN 130:119599
TI Pharmaceutical compositions comprising an **angiostatic** steroid combined with a hyaluronan for increasing neovascularization and **angiogenesis** during wound healing
IN Seed, Michael P.; Alam, Chandan; Willoughby, Derek A.
PA Hyal Pharmaceutical Corporation, Can.
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9901142	A1	19990114	WO 1998-CA649	19980703
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2208916	AA	19990103	CA 1997-2208916	19970703
AU 9882021	A1	19990125	AU 1998-82021	19980703
PRAI CA 1997-2208916		19970703		
WO 1998-CA649		19980703		

AB A pharmaceutical compn. is disclosed for increasing neovascularization and **angiogenesis** during wound healing in a mammal beyond the level of neovascularization and **angiogenesis** which would occur at the wound site without any treatment, the compn. comprising an effective amt. of any **angiostatic** steroid which has reduced or no deteriorative or detrimental side effects, combined with an effective amt. of a form of hyaluronan, e.g. hyaluronic acid or a pharmaceutically acceptable salt thereof.

IT **362-07-2 362-08-3**
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(**angiostatic** steroid-hyaluronan combination for increasing neovascularization and **angiogenesis** during wound healing)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:785662 HCAPLUS
DN 130:33040
TI Methods using 7-(substituted amino)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines for inhibiting **angiogenesis**, proliferation of endothelial or tumor cells, and tumor growth
IN Backer, Joseph M.; Bohlen, Peter
PA American Cyanamid Company, USA
SO U.S., 12 pp.
CODEN: USXXAM
DT **Patent**

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5843925	A	19981201	US 1994-354694	19941213
	US 5856315	A	19990105	US 1998-84484	19980526
PRAI	US 1994-354694		19941213		

OS MARPAT 130:33040
AB A method is provided for inhibiting **angiogenesis** and proliferation of endothelial cells by administering an inhibitory amt. of a 7-(substituted amino)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracycline (Markush included). Also provided is a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amt. of a compd. of the invention in combination with a chemotherapeutic agent or radiation therapy. Further provided are compns. contg. an effective inhibitory amt. of a compd. of the invention in a pharmaceutically acceptable carrier.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(deoxytetracycline prepn. for inhibiting **angiogenesis**, proliferation of endothelial or tumor cells, and tumor growth, and compns. with other agents)
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:778968 HCAPLUS
DN 130:105451
TI Inhibition of normal and experimental **angiotumor** endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol
AU Reiser, F.; Way, D.; Bernas, M.; Witte, M.; Witte, C.
CS Department of Surgery, The University of Arizona, Tucson, AZ, 85724, USA
SO Proc. Soc. Exp. Biol. Med. (1998), 219(3), 211-216
CODEN: PSEBAA; ISSN: 0037-9727
PB Blackwell Science, Inc.
DT Journal
LA English
AB With rapid growth and metab., aggressive cancers require an extensive vascular network, termed tumor **angiogenesis**. The body produces a variety of natural **angiogenic** inhibitors, among which is the mammalian **estrogen** metabolite, 2-methoxyestradiol (2-MeOE2). In this study, we compared the effects of 2-MeOE2 on a human umbilical vein cell line (HUVEC-C) and on an immortal, **angiotumor**-producing rat sinusoidal endothelial cell line (RSE-1). In vitro, the effects of varying concns. of 2-MeOE2 from 0.01-100.0 .mu.M were measured with cell counts and compared to control cells. HUVEC-C had an ED50 .apprx.3.5 .mu.M with .apprx.27% inhibition of cell growth whereas RSE-1 had an ED50 .apprx.2.2 .mu.M with .apprx.50% inhibition of cell growth compared with controls. The lowest concn. with maximal effect was 10.0 .mu.M 2-MeOE2 for both cell lines. Using this concn., flow cytometric anal. of cell cycles was performed with propidium iodide stained DNA of HUVEC-C and RSE-1 at 24 and 48 h. Both demonstrated a significant block at G2M of the cell cycle. At 48 h, HUVEC-C had 32% of cells in G2M (control = 9% G2M), and RSE-1 had 36% of cells in G2M (control = 18% G2M). These findings demonstrate a strong in vitro antiproliferative effect of 2-MeOE2 on normal dividing endothelial as well as **angiotumor** cells mediated through a cell cycle-specific block at G2M. The antiendothelial, **antiangiotumor** effect of 2-MeOE2 supports its potential as a therapeutic agent against solid organ cancers, benign or malignant vascular growths, and other pathol. states dependent on **angiogenesis**.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(methoxyestradiol inhibition of normal and exptl. **angiotumor**

endothelial cell proliferation and cell cycle progression)
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L71 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:369884 HCAPLUS
DN 129:90490
TI Is 2-methoxyestradiol an endogenous **estrogen** metabolite that inhibits mammary carcinogenesis?
AU Zhu, Bao Ting; Conney, Allan H.
CS Laboratory for Cancer Research, Department of Chemical Biology, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway, NJ, 08854-8020, USA
SO Cancer Res. (1998), 58(11), 2269-2277
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal; General Review
LA English
AB A review, with 172 refs. Catechol **estrogens** (2- or 4-hydroxyestradiol and 2- or 4-hydroxyestrone) are chem. reactive **estrogen** metabolites that are O-methylated to less polar monomethyl ethers by catechol-O-methyltransferase, an enzyme present in many tissues such as the liver, kidney, brain, placenta, uterus, and mammary gland. In the present report, the authors review recent studies on the antitumorigenic and **antiangiogenic** effects of exogenously administered 2-methoxyestradiol in vitro and in vivo. The authors also discuss data that suggest that endogenous formation of 2-methoxyestradiol (and its 2-hydroxyestradiol precursor) may have a protective effect on **estrogen**-induced cancers in target organs. Although the mol. mechanism of action of 2-methoxyestradiol is not clear, the authors suggest that some unique effects of 2-methoxyestradiol may be mediated by a specific intracellular effector or receptor that is refractory to the parent hormone, estradiol. Addnl. research is needed to identify factors that regulate the metabolic formation and disposition of 2-methoxyestradiol in liver and in target cells and to evaluate the effects of modulating 2-methoxyestradiol formation on **estrogen** -induced carcinogenesis.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); MFM (Metabolic formation); **THU (Therapeutic use)**; BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(methoxyestradiol antitumorigenic and **antiangiogenic** effects in vitro and in vivo)

L71 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:752842 HCAPLUS
DN 128:30711
TI Treatment of asthma and airway diseases using steroids or steroid analogs
IN Stewart, Alastair George
PA Amrad Operations Pty. Ltd., Australia; Stewart, Alastair George
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9742958	A1	19971120	WO 1997-AU286	19970509

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9726276	A1	19971205	AU 1997-26276	19970509
	AU 725048	B2	20001005		
	CN 1218401	A	19990602	CN 1997-194505	19970509
	EP 923376	A1	19990623	EP 1997-917945	19970509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 5962445	A	19991005	US 1997-853528	19970509
	JP 2000507923	T2	20000627	JP 1997-530434	19970509
	US 6200966	B1	20010313	US 1999-330918	19990611
PRAI	AU 1996-9766	A	19960509		
	AU 1996-9918	A	19960520		
	US 1997-853528	A1	19970509		
	WO 1997-AU286	W	19970509		

AB The invention relates to use of steroids or steroid analogs in the treatment of chronic and acute inflammation of the airways, particularly asthmatic conditions. It also relates to compds. and compns. which modulate airway remodelling. In a preferred embodiment, the active component inhibits inflammation and smooth muscle cell proliferation in the airway wall. It may also have a least one other activity selected from **antiangiogenesis**, antioxidn., and the ability to disrupt microtubule formation. In a preferred embodiment, the steroid is 2-methoxyoestradiol.

IT **362-07-2**, 2-Methoxyestradiol **362-08-3**, 2-Methoxyestrone
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of asthma and airway diseases using steroids or steroid analogs)

L71 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:483454 HCAPLUS
DN 127:91017
TI Method and composition for treatment of pathological conditions associated with **angiogenesis**
IN Fotsis, Theodore; Adlercreutz, Herman; Schweigerer, Lothar
PA Germany
SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 84,969, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643900	A	19970701	US 1995-405776	19950317
PRAI	US 1993-84969		19930702		

AB The present invention relates to a method and a compn. for the treatment of pathol. conditions assocd. with enhanced **angiogenesis**. The method comprises administering 2-methoxyestradiol to a subject in need of such treatment. 2-Methoxyestradiol also has potent pharmacol. properties in the treatment of solid tumors.

IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **angiogenic** diseases and solid tumors with 2-methoxyestradiol)

L71 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:84466 HCAPLUS
DN 126:140011
TI Suppression of type II collagen-induced arthritis by the endogenous **estrogen** metabolite 2-methoxyestradiol
AU Josefsson, Elisabet; Tarkowski, Andrej
CS University of Goteborg, Goteborg, Swed.
SO Arthritis Rheum. (1997), 40(1), 154-163
CODEN: ARHEAW; ISSN: 0004-3591
PB Lippincott-Raven
DT Journal

LA English
AB To evaluate the antiarthritic properties of 2-methoxyestradiol, an endogenous metabolite of estradiol, on type II collagen-induced arthritis (CIA) in DBA/1 mice, the effects of treatment with 2-methoxyestradiol on the development of CIA were evaluated clin. and histol. The in vitro effects of 2-methoxyestradiol on lymphocyte and endothelial cell proliferation and differentiation were analyzed by std. methods. The development of CIA was significantly suppressed by 2-methoxyestradiol. Incubation with 2-methoxyestradiol suppressed the in vitro proliferation of endothelial cells, indicating that this compd. down-regulates **angiogenesis**. Endothelial cell prodn. of nitric oxide (NO) was also down-regulated by 2-methoxyestradiol. In contrast to estradiol, 2-methoxyestradiol exerted neither detectable feminizing effects on the sex organs nor inhibition of leukocyte development in hematopoietic organs. The development of CIA is suppressed by 2-methoxyestradiol, possibly via inhibition of **angiogenesis**. Diminished NO prodn. could be of importance in vivo because it is a potent pro-inflammatory mediator. Since 2-methoxyestradiol exerts only mild side effects compared with estradiol, it is an interesting candidate for therapeutic use in inflammatory diseases.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(suppression of type II collagen-induced arthritis by endogenous **estrogen** metabolite 2-methoxyestradiol)

L71 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:39755 HCAPLUS
DN 126:127078
TI Inhibition of **angiogenesis** and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
AU Klauber, Nancy; Parangi, Sareh; Flynn, Evelyn; Hamel, Ernest; D'Amato, Robert J.
CS Department Surgery, Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA
SO Cancer Res. (1997), 57(1), 81-86
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB 2-Methoxyestradiol (2-ME), an endogenous **estrogen** metabolite which disrupts microtubule function, has been shown to inhibit proliferating cells in vitro and suppress certain murine tumors in vivo. In vitro screening has detd. that breast cancer cell lines are most sensitive to inhibition by 2-ME. Addnl., 2-ME has been shown to inhibit **angiogenesis** in vitro. We tested whether 2-ME suppresses cytokine-induced **angiogenesis** in vivo and inhibits growth of a human breast carcinoma in severe combined immunodeficient mice. A model of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in C57BL/6 mice was used to evaluate the **antiangiogenic** effects of 2-ME and other microtubule inhibitors such as Taxol, vincristine, and colchicine. 2-ME (150 mg/kg p.o.) inhibited bFGF and VEGF-induced neovascularization by 39% and 54%, resp. Taxol (6 mg/kg i.p.) inhibited bFGF and VEGF-induced neovascularization by 45% and 37%, resp. Vincristine (0.2 mg/kg i.p.) and colchicine (0.25 mg/kg i.p.) had no effect. Treatment with 2-ME (75 mg/kg p.o.) for 1 mo suppressed the growth of a human breast carcinoma in mice by 60% without toxicity. Recognition of the **antiangiogenic** and antitumor properties of 2-ME and taxol may be crucial in planning clin. applications to **angiogenesis**-dependent diseases.
IT **362-07-2**, 2-Methoxyestradiol
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(inhibition of **angiogenesis** and breast cancer in mice by microtubule inhibitors methoxyestradiol and taxol)

L71 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:640895 HCAPLUS
DN 125:292016
TI Inhibitors of **angiogenesis** in human urine
AU Fotsis, Theodore; Pepper, Michael S.; Aktas, Erkan; Joussen, Antonia; Kruse, Friedrich; Adelcreutz, Herman; Waehaelea, Kristina; Hase, Tapio; Montesano, Roberto; Schweigerer, Lothar
CS Children's University Hospital, University of Heidelberg, Heidelberg, 69120, Germany
SO NATO ASI Ser., Ser. A (1996), 285(Molecular, Cellular, and Clinical Aspects of Angiogenesis), 213-227
CODEN: NALSDJ; ISSN: 0258-1213
DT Journal; General Review
LA English
AB A review with .apprx.50 refs. on the authors' work in screening urine of human subjects consuming a diet rich in plant products for anti-**angiogenic** compds. The authors identified the isoflavonoid genistein, the endogenous **estrogen** metabolite 2-methoxyestradiol and metabolites of flavonoids that show inhibitory activities against **angiogenesis**. Irresp. of whether or not these substances play any physiol. role in humans, they might be suitable as pharmacol. agents for treatment of solid malignant tumors and other **angiogenic** diseases.
IT **362-07-2**, 2-Methoxyestradiol
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); **THU (Therapeutic use)**; BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(inhibitors of **angiogenesis** isolated from human urine in relation to antitumor activity and treatment of **angiogenic** diseases)

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:30:07 ON 19 FEB 2002

STRUCTURE FILE UPDATES: 18 FEB 2002 HIGHEST RN 393508-26-4
DICTIONARY FILE UPDATES: 18 FEB 2002 HIGHEST RN 393508-26-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the H/Z/CA/CAplus files between 12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches during this period, either directly appended to a CAS Registry Number or by qualifying an L-number with /P, may have yielded incomplete results. As of 1/23/02, the situation has been resolved. Also, note that searches conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator between 12/27/01 and 1/23/02, are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to help@cas.org for further assistance or to receive a credit for any duplicate searches.

=> d ide can tot 169

L69 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **383414-35-5** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2,2,2-trifluoroethyl)-, (17.beta.)-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 678473
FS STEREOSEARCH
MF C20 H25 F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



remaining hit compounds from references

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

L69 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **302799-37-7** REGISTRY
CN Estra-1,3,5(10)-triene-3,6,17-triol, 2-ethoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 683688
FS STEREOSEARCH
MF C20 H28 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

L69 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **192062-20-7** REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 2-ethoxy-3,17-dihydroxy-, O-methyloxime, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 683125
FS STEREOSEARCH
MF C21 H29 N O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **192062-15-0** REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 3,17-dihydroxy-2-(2,2,2-trifluoroethoxy)-, oxime, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 681683
FS STEREOSEARCH
MF C20 H24 F3 N O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **192062-14-9** REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 2-ethoxy-3,17-dihydroxy-, oxime, (17.beta.)-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 680185
FS STEREOSEARCH
MF C20 H27 N O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **192062-13-8** REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 3,17-dihydroxy-2-(2,2,2-trifluoroethoxy)-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 681684
FS STEREOSEARCH
MF C20 H23 F3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 133:322044

REFERENCE 3: 127:95444

L69 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **192062-12-7** REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 2-ethoxy-3,17-dihydroxy-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 679431
FS STEREOSEARCH
MF C20 H26 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 134:326663

REFERENCE 3: 133:322044

REFERENCE 4: 133:105195

REFERENCE 5: 132:303593

REFERENCE 6: 127:95444

L69 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **192062-02-5** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-propynyl)-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 682429
FS STEREOSEARCH
MF C21 H26 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 127:95444

L69 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **165619-13-6** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-pentenyl)-, [2(E),17.beta.]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H32 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **165619-12-5** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-butenyl)-, [2(E),17.beta.]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H30 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **165619-09-0** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-methylethoxy)-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **165619-08-9** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-propoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 123:112496

L69 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **165619-07-8** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-ethoxy-, (17.beta.)- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN 2-Ethoxyestradiol
CN NSC 671043
FS STEREOSEARCH
MF C20 H28 O3
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 134:326663

REFERENCE 3: 133:322044

REFERENCE 4: 132:303593

REFERENCE 5: 129:245330

REFERENCE 6: 127:95444

REFERENCE 7: 123:112496

L69 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **22415-44-7** REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 2-methoxy-, (17.alpha.)-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17-diol, 2-methoxy- (8CI)
OTHER NAMES:
CN 17.alpha.-Ethynyl-2-methoxyestradiol
CN 2-Methoxy-17.alpha.-ethynylestradiol
FS STEREOSEARCH
DR 26011-46-1
MF C21 H26 O3
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, MEDLINE, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
21 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:64669

REFERENCE 2: 132:132481

REFERENCE 3: 122:256433

REFERENCE 4: 118:161228

REFERENCE 5: 108:94834

REFERENCE 6: 104:1000

REFERENCE 7: 102:106508

REFERENCE 8: 101:48797

REFERENCE 9: 100:185989

REFERENCE 10: 100:17962

L69 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **362-08-3** REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy- (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estrone, 2-methoxy- (6CI)
OTHER NAMES:
CN 2-Hydroxyestrone 2-methyl ether
CN 2-Methoxyestrone
FS STEREOSEARCH
MF C19 H24 O3
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MEDLINE, SPECINFO, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

257 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
257 REFERENCES IN FILE CAPLUS (1967 TO DATE)
34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:79753

REFERENCE 2: 136:64669

REFERENCE 3: 136:31843

REFERENCE 4: 136:3843

REFERENCE 5: 135:366956

REFERENCE 6: 135:221459

REFERENCE 7: 135:195698

REFERENCE 8: 135:175599

REFERENCE 9: 135:147586

REFERENCE 10: 134:321936

L69 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2002 ACS
RN **362-07-2** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-methoxy- (7CI, 8CI)
CN Estradiol, 2-methoxy- (6CI)
OTHER NAMES:
CN 2-Hydroxyestradiol 2-methyl ether
CN 2-Methoxyestra-1,3,5(10)-triene-3,17.beta.-diol
CN 2-Methoxyestradiol
CN NSC 659853
FS STEREOSEARCH
MF C19 H26 O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

299 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
300 REFERENCES IN FILE CAPLUS (1967 TO DATE)
24 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:112738

REFERENCE 2: 136:79991

REFERENCE 3: 136:79754

REFERENCE 4: 136:79753

REFERENCE 5: 136:64669

REFERENCE 6: 136:48639

REFERENCE 7: 136:42803

REFERENCE 8: 136:31870

REFERENCE 9: 136:31843

REFERENCE 10: 136:31835

=> s l30 not l68
L72 64 L30 NOT L68

← remaining hits from structure search

=>
=> d ide can tot

L72 ANSWER 1 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 345317-45-5 REGISTRY
CN Estra-1,3,5(10)-trien-17-ol, 2-(2-propenyl)-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H28 O
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:56201

L72 ANSWER 2 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 302799-36-6 REGISTRY
CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-ethoxy-, hydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H29 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:322044

L72 ANSWER 3 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 300853-53-6 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (8.alpha.,9.beta.,13.alpha.,14.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ent-2-Methoxyestra-1,3,5(10)-triene-16.alpha.,17.beta.-diol
FS STEREOSEARCH
MF C19 H26 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:296594

L72 ANSWER 4 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 258278-77-2 REGISTRY
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-17-phenyl-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN EM 2318
FS STEREOSEARCH
MF C25 H27 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:152024

L72 ANSWER 5 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 258278-74-9 REGISTRY
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-17-propyl-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN EM 2132
FS STEREOSEARCH
MF C22 H29 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:152024

L72 ANSWER 6 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 258278-49-8 REGISTRY
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-17-(phenylmethyl)-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN EM 1836
FS STEREOSEARCH
MF C26 H29 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:152024

L72 ANSWER 7 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 229635-01-2 REGISTRY
CN 19-Norpregna-1,3,5(10),20-tetraene-3,17-diol, 2-methoxy-, (17.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H28 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:195698

REFERENCE 2: 131:88084

L72 ANSWER 8 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 192062-30-9 REGISTRY
CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-ethoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H29 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:95444

L72 ANSWER 9 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 192062-27-4 REGISTRY
CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-ethoxy-, hydrochloride, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H29 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (192062-30-9)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:95444

L72 ANSWER 10 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 192062-18-3 REGISTRY
CN Estra-1,3,5(10)-triene-3,6,17-triol, 2-ethoxy-, (6.alpha.,17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:322044

REFERENCE 2: 127:95444

L72 ANSWER 11 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 192062-17-2 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 6-amino-2-ethoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H29 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:95444

L72 ANSWER 12 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 192062-07-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2,2,2-trifluoroethoxy)-, (17.beta.)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H25 F3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:322044

REFERENCE 2: 129:245330

REFERENCE 3: 127:95444

L72 ANSWER 13 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 161762-25-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(3-aminopropyl)-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H31 N O2

SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 122:187857

L72 ANSWER 14 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 161762-24-9 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(3-hydroxypropyl)-, (17.beta.)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:31870

REFERENCE 2: 124:289981

REFERENCE 3: 122:187857

L72 ANSWER 15 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 161762-23-8 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2-aminoethyl)-, (17.beta.)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C20 H29 N O2

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 125:105405

REFERENCE 2: 122:187857

L72 ANSWER 16 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 161762-22-7 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(2-hydroxyethyl)-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:31870

REFERENCE 2: 124:289981

REFERENCE 3: 122:187857

L72 ANSWER 17 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 161762-21-6 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(aminomethyl)-, hydrochloride, (17.beta.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C19 H27 N O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 122:187857

L72 ANSWER 18 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 156669-41-9 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 4-bromo-2-methoxy-, (17.alpha.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Methoxy-4-bromo-17.alpha.-ethynylestradiol
CN 4-Bromo-2-methoxyethinylestradiol
FS STEREOSEARCH
MF C21 H25 Br O3
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 121:100057

L72 ANSWER 19 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 153654-78-5 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 2-(hydroxymethyl)-, (17.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H26 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: .120:192069

L72 ANSWER 20 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 144216-19-3 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2,4-bis(hydroxymethyl)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H26 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:212773

L72 ANSWER 21 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 144216-18-2 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-20-yne-2,4-dimethanol, 3,17-dihydroxy-,

(17.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H28 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:192069

REFERENCE 2: 117:212773

L72 ANSWER 22 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 144216-17-1 REGISTRY
CN Estra-1,3,5(10)-triene-2,4-dimethanol, 3,17-dihydroxy-, (17.beta.)- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:192069

REFERENCE 2: 117:212773

L72 ANSWER 23 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 141056-21-5 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 4-fluoro-3-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Methoxy-4-fluoroestrone
CN 4-Fluoro-2-methoxyestrone
FS STEREOSEARCH
MF C19 H23 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 116:207984

L72 ANSWER 24 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 119829-59-3 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-hydroxy-1-methylethyl)-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H30 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154665

L72 ANSWER 25 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 111443-37-9 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estrone, 2-(hydroxymethyl)- (6CI)
FS STEREOSEARCH
MF C19 H24 O3
SR CAOLD
LC STN Files: CA, CAOLD, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 120:192069

L72 ANSWER 26 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 98543-85-2 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(1-methyl-2-propenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-(1-methylallyl)- (7CI)
FS STEREOSEARCH
DR 175414-64-9
MF C22 H28 O2
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 124:260811

L72 ANSWER 27 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 97515-50-9 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 4-bromo-2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Bromo-2-methoxyestradiol
FS STEREOSEARCH
MF C19 H25 Br O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 111:233338

REFERENCE 2: 103:65176

L72 ANSWER 28 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 97515-47-4 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 4-fluoro-2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Fluoro-2-methoxyestradiol
FS STEREOSEARCH
MF C19 H25 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:146466

REFERENCE 2: 103:65176

L72 ANSWER 29 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 94761-90-7 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy-4-methyl- (7CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H26 O2
LC STN Files: BEILSTEIN*, CAOLD
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L72 ANSWER 30 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 94440-60-5 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(hydroxymethyl)-, (17.beta.)- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-(hydroxymethyl)- (7CI)
FS STEREOSEARCH
MF C19 H26 O3
LC STN Files: CA, CAOLD, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:31870

REFERENCE 2: 130:262306

REFERENCE 3: 125:105405

REFERENCE 4: 124:289981

REFERENCE 5: 122:187857

REFERENCE 6: 120:192069

L72 ANSWER 31 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 77736-30-2 REGISTRY
CN Estra-1,3,5(10)-triene-6,17-dione, 2-methoxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H22 O3
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 95:7573

L72 ANSWER 32 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 77736-29-9 REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 17-hydroxy-2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C19 H24 O3
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 95:7573

L72 ANSWER 33 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 77736-24-4 REGISTRY
CN Estra-1,3,5(10)-triene-6,17-dione, 3-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H22 O4
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 97:163313

REFERENCE 2: 95:7573

L72 ANSWER 34 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 69833-94-9 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy-, O-methyloxime (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C20 H27 N O3
LC STN Files: SPECINFO

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L72 ANSWER 35 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 69540-63-2 REGISTRY
CN Estra-1,3,5(10)-trien-6-one, 3,17-dihydroxy-2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
DR 77736-21-1
MF C19 H24 O4
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:295993

REFERENCE 2: 97:163313

REFERENCE 3: 95:7573

REFERENCE 4: 92:144013

REFERENCE 5: 92:108010

REFERENCE 6: 90:121859

L72 ANSWER 36 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 69505-03-9 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy-, (.+-.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H24 O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, GMELIN*
(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 93:114810

REFERENCE 2: 90:121861

L72 ANSWER 37 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 65968-97-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,4,17-triol, 2-methoxy-, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H26 O4
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 88:136839

L72 ANSWER 38 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 65968-96-9 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3,4-dihydroxy-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H28 O4
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 88:136839

L72 ANSWER 39 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 59939-20-7 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, hydrogen sulfate, (17.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H26 O3 . x H2 O4 S
LC STN Files: CA, CAPLUS

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 362-07-2
CMF C19 H26 O3

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 84:148461

L72 ANSWER 40 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 58562-34-8 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3,4-dihydroxy-2-methoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2,3,4-Trihydroxy-1,3,5(10)-estratrien-17-one 2-methyl ether
FS STEREOSEARCH
MF C19 H24 O4
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 88:136839

REFERENCE 2: 84:119044

REFERENCE 3: 84:102907

L72 ANSWER 41 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 52691-63-1 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-methyl-2-propenyl)-, [2(S),17.beta.]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H30 O2
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 80:146402

L72 ANSWER 42 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 52619-49-5 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(1-methyl-2-propenyl)-, (17.beta.)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H30 O2
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 80:146402

L72 ANSWER 43 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 51933-36-9 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-(2-chloro-2-propenyl)-3-hydroxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H25 Cl O2
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 81:91784

L72 ANSWER 44 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 42028-20-6 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy-4-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Methoxy-4-methylestrone
FS STEREOSEARCH
MF C20 H26 O3
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 79:27594

L72 ANSWER 45 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 42028-17-1 REGISTRY
CN Estra-1,3,5(10)-triene-1,17-diol, 2-methoxy-4-methyl-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-1,17.beta.-diol, 2-methoxy-4-methyl- (7CI)
FS STEREOSEARCH
MF C20 H28 O3
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 79:27594

L72 ANSWER 46 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 41259-43-2 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-azido-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Azidoestradiol
FS STEREOSEARCH
MF C18 H23 N3 O2
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:96907

REFERENCE 2: 101:123208

REFERENCE 3: 96:116050

REFERENCE 4: 94:99013

REFERENCE 5: 91:168869

REFERENCE 6: 80:78582

REFERENCE 7: 79:137346

L72 ANSWER 47 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 41164-50-5 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-azido-3-hydroxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Azidoestrone
FS STEREOSEARCH
MF C18 H21 N3 O2
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Absolute stereochemistry.



6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:96907

REFERENCE 2: 94:99013

REFERENCE 3: 92:53642

REFERENCE 4: 91:168869

REFERENCE 5: 80:78582

REFERENCE 6: 79:137346

L72 ANSWER 48 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 35577-55-0 REGISTRY
CN Estra-1,3,5(10)-trien-17-ol, 2-methoxy-4-methyl-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-trien-17.beta.-ol, 2-methoxy-4-methyl- (6CI, 7CI)
OTHER NAMES:
CN 2-Methoxy-4-methylestratriene-17.beta.-ol
FS STEREOSEARCH
MF C20 H28 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 79:27594

REFERENCE 2: 76:113417

L72 ANSWER 49 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 31559-55-4 REGISTRY
CN 19-Nor-17.alpha.-pregna-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H27 N O2
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 74:112314

L72 ANSWER 50 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 27293-73-8 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy- (8CI, 9CI) (CA INDEX NAME)
FS STEREOSEARCH
DR 27293-89-6
MF C19 H24 O2
LC STN Files: BEILSTEIN*, GMELIN*, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L72 ANSWER 51 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 22145-26-2 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-(phenylmethoxy)-, (17.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-(benzyloxy)- (8CI)
FS STEREOSEARCH
MF C25 H30 O3
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:317590

REFERENCE 2: 119:117610

REFERENCE 3: 77:101989

REFERENCE 4: 70:106759

L72 ANSWER 52 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 17553-16-1 REGISTRY
CN Estra-1,3,5(10)-trien-17.beta.-ol, 2-methoxy- (6CI, 7CI, 8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H26 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 73:116788

REFERENCE 2: 72:121765

REFERENCE 3: 68:69179

L72 ANSWER 53 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 16373-38-9 REGISTRY
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-methoxy-1-methyl- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 O3
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 67:117038

L72 ANSWER 54 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 10506-80-6 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-allyl-3-hydroxy- (7CI, 8CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estrone, 2-allyl- (6CI)
FS STEREOSEARCH
MF C21 H26 O2
LC STN Files: BEILSTEIN*, CAOLD
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L72 ANSWER 55 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 10506-67-9 REGISTRY
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2-allyl- (7CI, 8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H28 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 66:102215

L72 ANSWER 56 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 10332-20-4 REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17.alpha.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-3,17.alpha.-diol, 2-methoxy- (8CI)
FS STEREOSEARCH
MF C19 H26 O3
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:166220

REFERENCE 2: 105:146466

L72 ANSWER 57 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 7683-30-9 REGISTRY
CN 17H-Cyclopenta[a]phenanthren-17-one, 6,7,8,9,11,12,13,14,15,16-decahydro-3-hydroxy-2-methoxy-13-methyl- (8CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H24 O3
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L72 ANSWER 58 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 6564-02-9 REGISTRY
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3-hydroxy-17-oxo- (7CI, 8CI, 9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H21 N O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 113:191714

REFERENCE 2: 74:112314

L72 ANSWER 59 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 6562-00-1 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2-(1,1-dimethylallyl)-3-hydroxy- (7CI, 8CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C23 H30 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 70:68602

L72 ANSWER 60 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 5976-42-1 REGISTRY
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-, (17.beta.)- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17.beta.-dihydroxy- (7CI, 8CI)
FS STEREOSEARCH
MF C19 H23 N O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, IFICDB, IFIPAT,
IFIUDB
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 113:191714

REFERENCE 2: 74:112314

L72 ANSWER 61 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 4967-94-6 REGISTRY
CN Estra-1,3,5(10)-triene, 2-methoxy- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H26 O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 73:116788

REFERENCE 2: 70:78228

L72 ANSWER 62 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 4953-96-2 REGISTRY
CN Estra-1,3,5(10)-trien-3-ol, 2-methoxy- (7CI, 8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H26 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 70:78228

L72 ANSWER 63 OF 64 REGISTRY COPYRIGHT 2002 ACS

RN 2120-13-0 REGISTRY
CN Estra-1,3,5(10)-triene-3,17.beta.-diol, 2,4-diallyl- (7CI, 8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H32 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 66:102215

L72 ANSWER 64 OF 64 REGISTRY COPYRIGHT 2002 ACS
RN 2120-12-9 REGISTRY
CN Estra-1,3,5(10)-trien-17-one, 2,4-diallyl-3-hydroxy- (7CI, 8CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estrone, 2,4-diallyl- (6CI)
FS STEREOSEARCH
MF C24 H30 O2
LC STN Files: BEILSTEIN*, CAOLD
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)